- Immediately assess the patient's airway, breathing, circulation, and mental status.
- Administer epinephrine 0.2-0.5 mg (in adults) or 0.01 mg/kg up to 0.3 mg (in children) intramuscularly in a large muscle belly (eg, anterolateral thigh) every 5-10 minutes to manage symptoms. Intranasal epinephrine spray is a viable alternative to an autoinjector for anaphylaxis in some patients.
- Support circulatory collapse with IV fluid resuscitation concurrent with epinephrine as above.
- Adjunctive therapy with antihistamines (IV diphenhydramine) and inhaled or nebulized beta-agonists (albuterol) are often used. Liquid second-generation H1 blockers (eg, cetirizine) are often being used in place of diphenhydramine as they are less sedating, allowing better assessment of the patient's clinical status.
Foods and additives, inhalants, insect stings, and medications may be triggers. Pathogenesis involves systemic activation of mast cells and basophils resulting in the release of inflammatory mediators. This activation may be immunoglobulin E (IgE) (in the case of classical anaphylaxis) or non-IgE mediated (anaphylactoid reaction). In adults, multiple episodes of anaphylaxis (eg, related to drugs) should lead to a consideration of mastocytosis.
Anaphylactoid reactions mimic anaphylactic reactions and cannot be distinguished clinically aside from the fact that anaphylaxis is IgE mediated and as such requires patient sensitization of the offending trigger. Anaphylactoid reactions are not IgE mediated and occur without sensitization, as the offending trigger causes direct mast cell and basophil activation.
Delayed diagnosis and treatment predict poor prognosis. Immediate management involves removal of the triggering allergen if possible, epinephrine by intramuscular injection, and further evaluation and management.
Related topic: alpha-gal syndrome